Zuellig Pharma 收購拜耳旗下的 Zam-Buk 和 Vapex 品牌
This acquisition allows Zuellig Pharma to enhance its consumer healthcare offerings in the APAC region, tapping into established brands with significant market presence.
Acquisition of Zam-Buk and Vapex brands from Bayer to expand consumer healthcare portfolio.
Zuellig Pharma 通过收购拜耳的 Zam-Buk® 和 Vapex® 品牌，加强了其消费保健品组合。此次战略性收购旨在扩大 Zuellig Pharma 在亚洲消费保健品市场的业务范围和产品线，利用这些产品的既有品牌认知度和市场覆盖率。该交易凸显了 Zuellig Pharma 对其消费健康部门增长的承诺。
This acquisition allows Zuellig Pharma to enhance its consumer healthcare offerings in the APAC region, tapping into established brands with significant market presence. It signifies a strategic move to bolster its position in a growing market segment, potentially leading to increased accessibility of these products for consumers across various Asian countries and strengthening Zuellig Pharma's overall market share in consumer health.
The acquisition directly impacts the APAC region by expanding Zuellig Pharma's consumer healthcare portfolio with well-known brands, aiming to improve product accessibility and market penetration across multiple Asian markets.
Where this signal fits in the broader landscape.
https://www.zuelligpharma.com/news-insights/Zuellig-Pharma-Strengthens-Consumer-Healthcare-Portfolio-with-the-Acquisition-of-Zam-Buk-and-Vapex-Brands-from-Bayer
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
登录